Loading
A phase 2 trial of Eprenetapopt and Pegylated liposomal doxorubicin in Ovarian cancer, run by Aprea Therapeutics, completed.
p53 Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Study of PLD With APR-246 is a phase 2 interventional study registered as NCT03268382 by Aprea Therapeutics, with 36 participants recorded, started 2017-07-31 and reaching its primary completion in 2019-07-10. Interventions recorded: APR-246, Pegylated Liposomal Doxorubicin Hydrochloride (PLD). Conditions recorded: High-grade Serous Ovarian Cancer.
Linked to the idea "Is aneuploidy itself a druggable vulnerability?" because the registry names Eprenetapopt and Pegylated liposomal doxorubicin among its interventions and Ovarian cancer among its conditions. Registry record only: no result has been read by an editor.
Shares Pegylated liposomal doxorubicin, Platinum-resistant ovarian cancer, Ovarian cancer and the tag pipeline.
Shares Pegylated liposomal doxorubicin, Platinum-resistant ovarian cancer, Ovarian cancer and the tag pipeline.
Shares High-grade serous ovarian cancer, Ovarian cancer and the tag pipeline.
Shares Platinum-resistant ovarian cancer, Ovarian cancer and the tag pipeline.
Shares Pegylated liposomal doxorubicin, Platinum-resistant ovarian cancer, Ovarian cancer and the tag pipeline.
Shares Platinum-resistant ovarian cancer, Ovarian cancer and the tag pipeline.
Shares High-grade serous ovarian cancer, Ovarian cancer and the tag pipeline.
Shares Platinum-resistant ovarian cancer, Ovarian cancer and the tag pipeline.